NCT02409342 · OUTCOME
Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] · Source last updated 2023-03-15
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure MEAN
Unit Score on a scale
Interval / dispersion Standard Deviation
Time frame Baseline until data cut-off on 10 September 2018 (up to approximately 38 months) What was measured Change from baseline in each of the patient-reported lung cancer symptoms with use of the SILC scale. The SILC scale is a nine-item content valid self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a total symptom severity score. Each SILC symptom scale (dyspnea, cough, chest pain) score was calculated as the average of the component items (range 0 to 4). An increase in score suggested worsening in symptomatology. A symptom score change of 0.3 points for the dyspnea and cough scores was considered to be clinically significant; whereas a symptom score change of 0.5 points for the chest pain score was considered to be clinically significant.
Analysis population: Analysis was performed for the TC3 or IC3-WT Populations.
Groups in this outcome Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).
Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).
Atezolizumab Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 52 Atezolizumab 61
Reported measurements Chest Pain, Week 1 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 44 Atezolizumab 47
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.57 1.23 Not reported Not reported Not reported Atezolizumab 0.31 0.84 Not reported Not reported Not reported
Chest Pain, Week 2 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 42 Atezolizumab 48
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.42 1.13 Not reported Not reported Not reported Atezolizumab 0.33 0.85 Not reported Not reported Not reported
Chest Pain, Week 3 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 44 Atezolizumab 49
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.25 1.26 Not reported Not reported Not reported Atezolizumab 0.43 0.97 Not reported Not reported Not reported
Chest Pain, Week 4 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 41 Atezolizumab 49
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.15 1.21 Not reported Not reported Not reported Atezolizumab 0.43 1.08 Not reported Not reported Not reported
Chest Pain, Week 5 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 39 Atezolizumab 47
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.27 1.19 Not reported Not reported Not reported Atezolizumab 0.28 1.00 Not reported Not reported Not reported
Chest Pain, Week 6 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 33 Atezolizumab 48
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.30 1.26 Not reported Not reported Not reported Atezolizumab 0.25 0.85 Not reported Not reported Not reported
Chest Pain, Week 7 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 30 Atezolizumab 44
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.23 1.04 Not reported Not reported Not reported Atezolizumab 0.30 0.97 Not reported Not reported Not reported
Chest Pain, Week 8 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 29 Atezolizumab 44
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.17 1.12 Not reported Not reported Not reported Atezolizumab 0.20 0.82 Not reported Not reported Not reported
Chest Pain, Week 9 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 31 Atezolizumab 47
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.27 1.00 Not reported Not reported Not reported Atezolizumab 0.33 1.07 Not reported Not reported Not reported
Chest Pain, Week 10 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 30 Atezolizumab 40
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.30 1.13 Not reported Not reported Not reported Atezolizumab 0.25 1.12 Not reported Not reported Not reported
Chest Pain, Week 11 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 29 Atezolizumab 34
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.26 1.32 Not reported Not reported Not reported Atezolizumab 0.21 0.96 Not reported Not reported Not reported
Chest Pain, Week 12 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 32 Atezolizumab 40
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.22 1.33 Not reported Not reported Not reported Atezolizumab 0.33 0.97 Not reported Not reported Not reported
Chest Pain, Week 13 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 28 Atezolizumab 38
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.07 1.17 Not reported Not reported Not reported Atezolizumab 0.30 1.04 Not reported Not reported Not reported
Chest Pain, Week 14 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 28 Atezolizumab 35
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.07 1.16 Not reported Not reported Not reported Atezolizumab 0.27 0.85 Not reported Not reported Not reported
Chest Pain, Week 15 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 30 Atezolizumab 40
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.10 1.23 Not reported Not reported Not reported Atezolizumab 0.45 1.01 Not reported Not reported Not reported
Chest Pain, Week 16 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 25 Atezolizumab 32
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 1.20 Not reported Not reported Not reported Atezolizumab 0.19 0.99 Not reported Not reported Not reported
Chest Pain, Week 17 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 27 Atezolizumab 34
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.22 1.41 Not reported Not reported Not reported Atezolizumab 0.22 1.20 Not reported Not reported Not reported
Chest Pain, Week 18 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 23 Atezolizumab 37
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.11 1.26 Not reported Not reported Not reported Atezolizumab 0.26 0.85 Not reported Not reported Not reported
Chest Pain, Week 19 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 22 Atezolizumab 32
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.11 1.01 Not reported Not reported Not reported Atezolizumab 0.23 0.94 Not reported Not reported Not reported
Chest Pain, Week 20 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 22 Atezolizumab 35
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.20 1.32 Not reported Not reported Not reported Atezolizumab 0.23 0.95 Not reported Not reported Not reported
Chest Pain, Week 21 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 18 Atezolizumab 36
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.03 0.83 Not reported Not reported Not reported Atezolizumab 0.11 0.87 Not reported Not reported Not reported
Chest Pain, Week 22 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 20 Atezolizumab 35
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.30 1.35 Not reported Not reported Not reported Atezolizumab 0.19 1.02 Not reported Not reported Not reported
Chest Pain, Week 23 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 16 Atezolizumab 33
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 1.00 Not reported Not reported Not reported Atezolizumab 0.33 0.84 Not reported Not reported Not reported
Chest Pain, Week 24 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 16 Atezolizumab 33
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.09 0.88 Not reported Not reported Not reported Atezolizumab 0.18 1.13 Not reported Not reported Not reported
Chest Pain, Week 25 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 29
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.27 0.79 Not reported Not reported Not reported Atezolizumab 0.29 0.87 Not reported Not reported Not reported
Chest Pain, Week 26 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 13 Atezolizumab 32
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.12 1.31 Not reported Not reported Not reported Atezolizumab 0.11 0.72 Not reported Not reported Not reported
Chest Pain, Week 27 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 32
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.05 1.15 Not reported Not reported Not reported Atezolizumab 0.20 0.80 Not reported Not reported Not reported
Chest Pain, Week 28 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 30
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 0.81 Not reported Not reported Not reported Atezolizumab 0.23 0.98 Not reported Not reported Not reported
Chest Pain, Week 29 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 12 Atezolizumab 28
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.25 0.87 Not reported Not reported Not reported Atezolizumab 0.18 0.80 Not reported Not reported Not reported
Chest Pain, Week 30 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 12 Atezolizumab 30
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.21 1.45 Not reported Not reported Not reported Atezolizumab 0.32 0.95 Not reported Not reported Not reported
Chest Pain, Week 31 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 29
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.18 1.72 Not reported Not reported Not reported Atezolizumab 0.33 0.90 Not reported Not reported Not reported
Chest Pain, Week 32 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 23
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.41 1.61 Not reported Not reported Not reported Atezolizumab 0.35 1.20 Not reported Not reported Not reported
Chest Pain, Week 33 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 13 Atezolizumab 26
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 1.44 Not reported Not reported Not reported Atezolizumab 0.04 1.03 Not reported Not reported Not reported
Chest Pain, Week 34 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 10 Atezolizumab 26
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.40 1.31 Not reported Not reported Not reported Atezolizumab 0.31 0.98 Not reported Not reported Not reported
Chest Pain, Week 35 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 27
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 1.16 Not reported Not reported Not reported Atezolizumab 0.28 1.13 Not reported Not reported Not reported
Chest Pain, Week 36 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 9 Atezolizumab 25
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.06 0.85 Not reported Not reported Not reported Atezolizumab 0.08 0.95 Not reported Not reported Not reported
Chest Pain, Week 37 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 8 Atezolizumab 23
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.31 1.25 Not reported Not reported Not reported Atezolizumab 0.39 0.89 Not reported Not reported Not reported
Chest Pain, Week 38 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 21
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.23 0.72 Not reported Not reported Not reported Atezolizumab 0.31 1.20 Not reported Not reported Not reported
Chest Pain, Week 39 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 9 Atezolizumab 22
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.22 1.00 Not reported Not reported Not reported Atezolizumab 0.14 0.92 Not reported Not reported Not reported
Chest Pain, Week 40 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 7 Atezolizumab 23
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.43 1.02 Not reported Not reported Not reported Atezolizumab 0.30 1.21 Not reported Not reported Not reported
Chest Pain, Week 41 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 7 Atezolizumab 20
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.36 1.07 Not reported Not reported Not reported Atezolizumab 0.30 1.01 Not reported Not reported Not reported
Chest Pain, Week 42 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 6 Atezolizumab 20
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.25 1.04 Not reported Not reported Not reported Atezolizumab 0.33 1.05 Not reported Not reported Not reported
Chest Pain, Week 43 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 5 Atezolizumab 20
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.30 1.15 Not reported Not reported Not reported Atezolizumab 0.18 1.29 Not reported Not reported Not reported
Chest Pain, Week 44 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 7 Atezolizumab 19
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.14 0.99 Not reported Not reported Not reported Atezolizumab 0.42 1.15 Not reported Not reported Not reported
Chest Pain, Week 45 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 21
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.63 0.48 Not reported Not reported Not reported Atezolizumab 0.31 0.90 Not reported Not reported Not reported
Chest Pain, Week 46 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 5 Atezolizumab 19
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.30 0.45 Not reported Not reported Not reported Atezolizumab 0.37 0.93 Not reported Not reported Not reported
Chest Pain, Week 47 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 18
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.71 Not reported Not reported Not reported Atezolizumab 0.31 0.86 Not reported Not reported Not reported
Chest Pain, Week 48 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 15
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.50 Not reported Not reported Not reported Atezolizumab 0.17 0.79 Not reported Not reported Not reported
Chest Pain, Week 49 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 17
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.00 1.32 Not reported Not reported Not reported Atezolizumab 0.47 1.07 Not reported Not reported Not reported
Chest Pain, Week 50 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 5 Atezolizumab 15
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.80 0.91 Not reported Not reported Not reported Atezolizumab 0.20 0.92 Not reported Not reported Not reported
Chest Pain, Week 51 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 16
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.88 0.85 Not reported Not reported Not reported Atezolizumab 0.31 0.89 Not reported Not reported Not reported
Chest Pain, Week 52 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.75 1.19 Not reported Not reported Not reported Atezolizumab 0.54 1.11 Not reported Not reported Not reported
Chest Pain, Week 53 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 5 Atezolizumab 12
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.70 0.84 Not reported Not reported Not reported Atezolizumab 0.29 1.08 Not reported Not reported Not reported
Chest Pain, Week 54 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 14
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.13 1.03 Not reported Not reported Not reported Atezolizumab 0.25 0.87 Not reported Not reported Not reported
Chest Pain, Week 55 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.17 1.26 Not reported Not reported Not reported Atezolizumab 0.15 0.99 Not reported Not reported Not reported
Chest Pain, Week 56 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 14
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.38 0.48 Not reported Not reported Not reported Atezolizumab 0.29 0.96 Not reported Not reported Not reported
Chest Pain, Week 57 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.67 0.58 Not reported Not reported Not reported Atezolizumab 0.08 0.73 Not reported Not reported Not reported
Chest Pain, Week 58 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.17 1.04 Not reported Not reported Not reported Atezolizumab 0.19 1.07 Not reported Not reported Not reported
Chest Pain, Week 59 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.00 0.87 Not reported Not reported Not reported Atezolizumab 0.00 0.87 Not reported Not reported Not reported
Chest Pain, Week 60 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 1.41 Not reported Not reported Not reported Atezolizumab 0.38 1.08 Not reported Not reported Not reported
Chest Pain, Week 61 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 14
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.00 0.87 Not reported Not reported Not reported Atezolizumab 0.36 1.12 Not reported Not reported Not reported
Chest Pain, Week 62 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 14
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.83 0.76 Not reported Not reported Not reported Atezolizumab 0.43 1.16 Not reported Not reported Not reported
Chest Pain, Week 63 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 12
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.71 Not reported Not reported Not reported Atezolizumab 0.29 0.86 Not reported Not reported Not reported
Chest Pain, Week 64 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 10
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.40 1.22 Not reported Not reported Not reported
Chest Pain, Week 65 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.35 1.11 Not reported Not reported Not reported
Chest Pain, Week 66 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 11
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.45 1.44 Not reported Not reported Not reported
Chest Pain, Week 67 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 11
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.00 1.41 Not reported Not reported Not reported Atezolizumab -0.09 0.80 Not reported Not reported Not reported
Chest Pain, Week 68 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.75 1.06 Not reported Not reported Not reported Atezolizumab 0.39 1.45 Not reported Not reported Not reported
Chest Pain, Week 69 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 10
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.71 Not reported Not reported Not reported Atezolizumab 0.50 1.33 Not reported Not reported Not reported
Chest Pain, Week 70 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 11
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.00 1.41 Not reported Not reported Not reported Atezolizumab 0.18 0.81 Not reported Not reported Not reported
Chest Pain, Week 71 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 10
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.71 Not reported Not reported Not reported Atezolizumab 0.45 1.32 Not reported Not reported Not reported
Chest Pain, Week 72 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 12
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.00 Not reported Not reported Not reported Not reported Atezolizumab 0.42 1.18 Not reported Not reported Not reported
Chest Pain, Week 73 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 11
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.50 Not reported Not reported Not reported Not reported Atezolizumab 0.27 1.19 Not reported Not reported Not reported
Chest Pain, Week 74 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.71 Not reported Not reported Not reported Atezolizumab 0.50 1.30 Not reported Not reported Not reported
Chest Pain, Week 75 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.75 1.06 Not reported Not reported Not reported Atezolizumab 0.33 1.32 Not reported Not reported Not reported
Chest Pain, Week 76 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 8
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.71 Not reported Not reported Not reported Atezolizumab 0.00 0.93 Not reported Not reported Not reported
Chest Pain, Week 77 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 8
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.71 Not reported Not reported Not reported Atezolizumab 0.19 1.33 Not reported Not reported Not reported
Chest Pain, Week 78 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.00 1.41 Not reported Not reported Not reported Atezolizumab 0.21 1.44 Not reported Not reported Not reported
Chest Pain, Week 79 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 8
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.71 Not reported Not reported Not reported Atezolizumab 0.31 1.31 Not reported Not reported Not reported
Chest Pain, Week 80 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.75 1.06 Not reported Not reported Not reported Atezolizumab 0.72 1.70 Not reported Not reported Not reported
Chest Pain, Week 81 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.75 1.06 Not reported Not reported Not reported Atezolizumab 0.08 1.72 Not reported Not reported Not reported
Chest Pain, Week 82 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.08 1.24 Not reported Not reported Not reported
Chest Pain, Week 83 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.50 1.48 Not reported Not reported Not reported
Chest Pain, Week 84 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 Not reported Not reported Not reported Not reported Atezolizumab 0.43 1.43 Not reported Not reported Not reported
Chest Pain, Week 85 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 8
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.38 1.41 Not reported Not reported Not reported
Chest Pain, Week 86 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.21 1.44 Not reported Not reported Not reported
Chest Pain, Week 87 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.29 1.41 Not reported Not reported Not reported
Chest Pain, Week 88 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.43 1.17 Not reported Not reported Not reported
Chest Pain, Week 89 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 5
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab -0.20 0.91 Not reported Not reported Not reported
Chest Pain, Week 90 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.07 1.13 Not reported Not reported Not reported
Chest Pain, Week 91 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab -0.07 0.89 Not reported Not reported Not reported
Chest Pain, Week 92 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.33 1.54 Not reported Not reported Not reported
Chest Pain, Week 93 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 1.47 Not reported Not reported Not reported
Chest Pain, Week 94 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 5
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.20 1.35 Not reported Not reported Not reported
Chest Pain, Week 95 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.33 1.54 Not reported Not reported Not reported
Chest Pain, Week 96 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.33 1.54 Not reported Not reported Not reported
Chest Pain, Week 97 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 1.47 Not reported Not reported Not reported
Chest Pain, Week 98 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.33 1.54 Not reported Not reported Not reported
Chest Pain, Week 99 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 4
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.88 1.18 Not reported Not reported Not reported
Chest Pain, Week 100 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 5
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 1.00 Not reported Not reported Not reported
Chest Pain, Week 101 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.83 0.93 Not reported Not reported Not reported
Chest Pain, Week 102 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 5
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 1.00 Not reported Not reported Not reported
Chest Pain, Week 103 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 4
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.63 1.11 Not reported Not reported Not reported
Chest Pain, Week 104 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 3
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.00 1.00 Not reported Not reported Not reported
Chest Pain, Week 105 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 3
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.00 1.00 Not reported Not reported Not reported
Chest Pain, Week 106 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 0.71 Not reported Not reported Not reported
Chest Pain, Week 107 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 3
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.00 1.00 Not reported Not reported Not reported
Chest Pain, Week 108 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.50 0.71 Not reported Not reported Not reported
Chest Pain, Week 109 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.75 1.06 Not reported Not reported Not reported
Chest Pain, Week 110 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 1.41 Not reported Not reported Not reported
Chest Pain, Week 111 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.50 0.71 Not reported Not reported Not reported
Chest Pain, Week 112 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.50 0.71 Not reported Not reported Not reported
Chest Pain, Week 113 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.50 0.71 Not reported Not reported Not reported
Chest Pain, Week 114 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 1.41 Not reported Not reported Not reported
Chest Pain, Week 115 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.75 1.06 Not reported Not reported Not reported
Chest Pain, Week 116 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 1.41 Not reported Not reported Not reported
Chest Pain, Week 117 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 1.41 Not reported Not reported Not reported
Chest Pain, Week 118 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 1.41 Not reported Not reported Not reported
Chest Pain, Week 119 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.75 1.06 Not reported Not reported Not reported
Chest Pain, Week 120 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.50 Not reported Not reported Not reported Not reported
Chest Pain, Week 121 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Chest Pain, Week 122 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 3.00 Not reported Not reported Not reported Not reported
Chest Pain, Week 123 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.50 Not reported Not reported Not reported Not reported
Chest Pain, Week 124 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 3.00 Not reported Not reported Not reported Not reported
Chest Pain, Week 125 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 3.00 Not reported Not reported Not reported Not reported
Chest Pain, Week 126 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 3.00 Not reported Not reported Not reported Not reported
Chest Pain, Week 127 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Chest Pain, Week 128 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 3.00 Not reported Not reported Not reported Not reported
Chest Pain, Week 129 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 3.00 Not reported Not reported Not reported Not reported
Chest Pain, Week 130 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Chest Pain, Week 131 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Cough, Week 1 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 44 Atezolizumab 47
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.13 0.86 Not reported Not reported Not reported Atezolizumab 0.10 0.70 Not reported Not reported Not reported
Cough, Week 2 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 42 Atezolizumab 48
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.01 0.99 Not reported Not reported Not reported Atezolizumab 0.19 0.75 Not reported Not reported Not reported
Cough, Week 3 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 44 Atezolizumab 49
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.03 0.76 Not reported Not reported Not reported Atezolizumab -0.01 0.76 Not reported Not reported Not reported
Cough, Week 4 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 41 Atezolizumab 49
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.02 1.02 Not reported Not reported Not reported Atezolizumab -0.03 0.98 Not reported Not reported Not reported
Cough, Week 5 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 39 Atezolizumab 47
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.01 0.84 Not reported Not reported Not reported Atezolizumab 0.00 0.96 Not reported Not reported Not reported
Cough, Week 6 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 33 Atezolizumab 48
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.18 0.93 Not reported Not reported Not reported Atezolizumab -0.18 0.89 Not reported Not reported Not reported
Cough, Week 7 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 30 Atezolizumab 44
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.20 0.92 Not reported Not reported Not reported Atezolizumab -0.06 0.98 Not reported Not reported Not reported
Cough, Week 8 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 29 Atezolizumab 44
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.10 0.90 Not reported Not reported Not reported Atezolizumab -0.13 0.91 Not reported Not reported Not reported
Cough, Week 9 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 31 Atezolizumab 47
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.24 0.86 Not reported Not reported Not reported Atezolizumab -0.06 1.01 Not reported Not reported Not reported
Cough, Week 10 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 30 Atezolizumab 40
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.07 1.12 Not reported Not reported Not reported Atezolizumab -0.10 1.02 Not reported Not reported Not reported
Cough, Week 11 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 29 Atezolizumab 34
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.02 1.24 Not reported Not reported Not reported Atezolizumab -0.07 1.07 Not reported Not reported Not reported
Cough, Week 12 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 32 Atezolizumab 40
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.08 1.30 Not reported Not reported Not reported Atezolizumab -0.09 0.97 Not reported Not reported Not reported
Cough, Week 13 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 28 Atezolizumab 38
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.09 1.22 Not reported Not reported Not reported Atezolizumab -0.20 0.93 Not reported Not reported Not reported
Cough, Week 14 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 28 Atezolizumab 35
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.20 1.19 Not reported Not reported Not reported Atezolizumab -0.07 0.95 Not reported Not reported Not reported
Cough, Week 15 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 30 Atezolizumab 40
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.05 1.35 Not reported Not reported Not reported Atezolizumab -0.19 1.04 Not reported Not reported Not reported
Cough, Week 16 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 25 Atezolizumab 32
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.10 1.06 Not reported Not reported Not reported Atezolizumab -0.19 0.94 Not reported Not reported Not reported
Cough, Week 17 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 27 Atezolizumab 34
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.04 0.99 Not reported Not reported Not reported Atezolizumab -0.21 1.09 Not reported Not reported Not reported
Cough, Week 18 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 23 Atezolizumab 37
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.02 1.23 Not reported Not reported Not reported Atezolizumab -0.26 0.93 Not reported Not reported Not reported
Cough, Week 19 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 22 Atezolizumab 32
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.23 1.29 Not reported Not reported Not reported Atezolizumab -0.27 0.87 Not reported Not reported Not reported
Cough, Week 20 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 22 Atezolizumab 35
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 1.33 Not reported Not reported Not reported Atezolizumab -0.33 0.95 Not reported Not reported Not reported
Cough, Week 21 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 18 Atezolizumab 36
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.17 1.40 Not reported Not reported Not reported Atezolizumab -0.19 0.88 Not reported Not reported Not reported
Cough, Week 22 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 20 Atezolizumab 35
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.20 1.32 Not reported Not reported Not reported Atezolizumab -0.17 0.89 Not reported Not reported Not reported
Cough, Week 23 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 16 Atezolizumab 33
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.22 1.18 Not reported Not reported Not reported Atezolizumab 0.05 0.90 Not reported Not reported Not reported
Cough, Week 24 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 16 Atezolizumab 33
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.13 1.51 Not reported Not reported Not reported Atezolizumab -0.12 0.80 Not reported Not reported Not reported
Cough, Week 25 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 29
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.45 0.96 Not reported Not reported Not reported Atezolizumab 0.14 0.82 Not reported Not reported Not reported
Cough, Week 26 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 13 Atezolizumab 32
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.46 1.20 Not reported Not reported Not reported Atezolizumab -0.03 0.89 Not reported Not reported Not reported
Cough, Week 27 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 32
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.50 1.22 Not reported Not reported Not reported Atezolizumab -0.05 0.94 Not reported Not reported Not reported
Cough, Week 28 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 30
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.45 0.88 Not reported Not reported Not reported Atezolizumab 0.08 0.84 Not reported Not reported Not reported
Cough, Week 29 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 12 Atezolizumab 28
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.50 1.31 Not reported Not reported Not reported Atezolizumab 0.05 0.67 Not reported Not reported Not reported
Cough, Week 30 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 12 Atezolizumab 30
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.88 1.13 Not reported Not reported Not reported Atezolizumab 0.12 0.88 Not reported Not reported Not reported
Cough, Week 31 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 29
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.86 1.40 Not reported Not reported Not reported Atezolizumab 0.05 0.74 Not reported Not reported Not reported
Cough, Week 32 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 23
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.73 1.56 Not reported Not reported Not reported Atezolizumab -0.04 1.04 Not reported Not reported Not reported
Cough, Week 33 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 13 Atezolizumab 26
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.77 1.13 Not reported Not reported Not reported Atezolizumab -0.29 1.06 Not reported Not reported Not reported
Cough, Week 34 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 10 Atezolizumab 26
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.80 1.18 Not reported Not reported Not reported Atezolizumab -0.02 0.75 Not reported Not reported Not reported
Cough, Week 35 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 27
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.14 0.95 Not reported Not reported Not reported Atezolizumab -0.09 1.10 Not reported Not reported Not reported
Cough, Week 36 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 9 Atezolizumab 25
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.17 0.66 Not reported Not reported Not reported Atezolizumab -0.36 1.16 Not reported Not reported Not reported
Cough, Week 37 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 8 Atezolizumab 23
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.25 0.89 Not reported Not reported Not reported Atezolizumab -0.04 0.84 Not reported Not reported Not reported
Cough, Week 38 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 21
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.05 0.88 Not reported Not reported Not reported Atezolizumab -0.07 1.11 Not reported Not reported Not reported
Cough, Week 39 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 9 Atezolizumab 22
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.50 0.90 Not reported Not reported Not reported Atezolizumab -0.20 0.97 Not reported Not reported Not reported
Cough, Week 40 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 7 Atezolizumab 23
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.36 0.94 Not reported Not reported Not reported Atezolizumab -0.39 1.23 Not reported Not reported Not reported
Cough, Week 41 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 7 Atezolizumab 20
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.21 0.57 Not reported Not reported Not reported Atezolizumab 0.05 0.84 Not reported Not reported Not reported
Cough, Week 42 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 6 Atezolizumab 20
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.17 0.52 Not reported Not reported Not reported Atezolizumab -0.20 1.16 Not reported Not reported Not reported
Cough, Week 43 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 5 Atezolizumab 20
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.10 0.55 Not reported Not reported Not reported Atezolizumab 0.03 1.06 Not reported Not reported Not reported
Cough, Week 44 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 7 Atezolizumab 19
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.36 0.94 Not reported Not reported Not reported Atezolizumab -0.11 1.09 Not reported Not reported Not reported
Cough, Week 45 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 21
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.25 0.50 Not reported Not reported Not reported Atezolizumab -0.26 0.92 Not reported Not reported Not reported
Cough, Week 46 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 5 Atezolizumab 19
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.10 0.96 Not reported Not reported Not reported Atezolizumab 0.08 0.85 Not reported Not reported Not reported
Cough, Week 47 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 18
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.58 Not reported Not reported Not reported Atezolizumab -0.03 0.90 Not reported Not reported Not reported
Cough, Week 48 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 15
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.17 0.29 Not reported Not reported Not reported Atezolizumab 0.23 0.68 Not reported Not reported Not reported
Cough, Week 49 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 17
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.67 0.76 Not reported Not reported Not reported Atezolizumab 0.26 0.85 Not reported Not reported Not reported
Cough, Week 50 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 5 Atezolizumab 15
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.30 0.76 Not reported Not reported Not reported Atezolizumab 0.00 0.85 Not reported Not reported Not reported
Cough, Week 51 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 16
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.13 0.63 Not reported Not reported Not reported Atezolizumab 0.06 0.93 Not reported Not reported Not reported
Cough, Week 52 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.63 0.95 Not reported Not reported Not reported Atezolizumab 0.27 0.97 Not reported Not reported Not reported
Cough, Week 53 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 5 Atezolizumab 12
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.70 0.76 Not reported Not reported Not reported Atezolizumab 0.38 0.71 Not reported Not reported Not reported
Cough, Week 54 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 14
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.41 Not reported Not reported Not reported Atezolizumab 0.07 0.70 Not reported Not reported Not reported
Cough, Week 55 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.67 0.29 Not reported Not reported Not reported Atezolizumab 0.12 0.94 Not reported Not reported Not reported
Cough, Week 56 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 14
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.41 Not reported Not reported Not reported Atezolizumab 0.14 0.97 Not reported Not reported Not reported
Cough, Week 57 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.50 Not reported Not reported Not reported Atezolizumab 0.15 0.66 Not reported Not reported Not reported
Cough, Week 58 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.67 0.29 Not reported Not reported Not reported Atezolizumab 0.08 1.00 Not reported Not reported Not reported
Cough, Week 59 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.33 0.58 Not reported Not reported Not reported Atezolizumab 0.06 0.63 Not reported Not reported Not reported
Cough, Week 60 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.75 0.35 Not reported Not reported Not reported Atezolizumab -0.04 0.83 Not reported Not reported Not reported
Cough, Week 61 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 14
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.50 Not reported Not reported Not reported Atezolizumab 0.00 0.88 Not reported Not reported Not reported
Cough, Week 62 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 14
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.33 0.58 Not reported Not reported Not reported Atezolizumab 0.14 0.79 Not reported Not reported Not reported
Cough, Week 63 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 12
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 0.00 Not reported Not reported Not reported Atezolizumab -0.04 0.86 Not reported Not reported Not reported
Cough, Week 64 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 10
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.35 1.00 Not reported Not reported Not reported
Cough, Week 65 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 Not reported Not reported Not reported Not reported Atezolizumab 0.12 0.92 Not reported Not reported Not reported
Cough, Week 66 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 11
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.45 1.21 Not reported Not reported Not reported
Cough, Week 67 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 11
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.25 0.35 Not reported Not reported Not reported Atezolizumab -0.09 0.66 Not reported Not reported Not reported
Cough, Week 68 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.25 0.35 Not reported Not reported Not reported Atezolizumab 0.61 1.29 Not reported Not reported Not reported
Cough, Week 69 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 10
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.25 0.35 Not reported Not reported Not reported Atezolizumab 0.50 1.18 Not reported Not reported Not reported
Cough, Week 70 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 11
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.25 0.35 Not reported Not reported Not reported Atezolizumab 0.23 0.79 Not reported Not reported Not reported
Cough, Week 71 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 10
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 0.00 Not reported Not reported Not reported Atezolizumab 0.55 0.90 Not reported Not reported Not reported
Cough, Week 72 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 12
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) -0.50 Not reported Not reported Not reported Not reported Atezolizumab 0.42 0.93 Not reported Not reported Not reported
Cough, Week 73 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 11
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.64 1.07 Not reported Not reported Not reported
Cough, Week 74 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 0.00 Not reported Not reported Not reported Atezolizumab 0.56 1.04 Not reported Not reported Not reported
Cough, Week 75 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 0.71 Not reported Not reported Not reported Atezolizumab 0.67 1.35 Not reported Not reported Not reported
Cough, Week 76 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 8
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.25 0.35 Not reported Not reported Not reported Atezolizumab 0.31 1.00 Not reported Not reported Not reported
Cough, Week 77 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 8
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 0.00 Not reported Not reported Not reported Atezolizumab 0.56 1.15 Not reported Not reported Not reported
Cough, Week 78 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.25 0.35 Not reported Not reported Not reported Atezolizumab 0.36 1.03 Not reported Not reported Not reported
Cough, Week 79 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 8
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 0.00 Not reported Not reported Not reported Atezolizumab 0.63 1.19 Not reported Not reported Not reported
Cough, Week 80 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.25 0.35 Not reported Not reported Not reported Atezolizumab 0.33 0.90 Not reported Not reported Not reported
Cough, Week 81 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.25 0.35 Not reported Not reported Not reported Atezolizumab 0.58 1.28 Not reported Not reported Not reported
Cough, Week 82 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.25 1.08 Not reported Not reported Not reported
Cough, Week 83 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.67 1.21 Not reported Not reported Not reported
Cough, Week 84 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 Not reported Not reported Not reported Not reported Atezolizumab 0.29 0.95 Not reported Not reported Not reported
Cough, Week 85 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 8
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.38 1.03 Not reported Not reported Not reported
Cough, Week 86 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.57 1.24 Not reported Not reported Not reported
Cough, Week 87 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.64 1.35 Not reported Not reported Not reported
Cough, Week 88 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.64 1.14 Not reported Not reported Not reported
Cough, Week 89 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 5
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 1.32 Not reported Not reported Not reported
Cough, Week 90 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.43 1.10 Not reported Not reported Not reported
Cough, Week 91 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 1.19 Not reported Not reported Not reported
Cough, Week 92 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.67 1.21 Not reported Not reported Not reported
Cough, Week 93 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.79 1.38 Not reported Not reported Not reported
Cough, Week 94 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 5
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.30 0.97 Not reported Not reported Not reported
Cough, Week 95 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.67 1.25 Not reported Not reported Not reported
Cough, Week 96 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.58 1.20 Not reported Not reported Not reported
Cough, Week 97 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.57 1.13 Not reported Not reported Not reported
Cough, Week 98 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.67 1.25 Not reported Not reported Not reported
Cough, Week 99 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 4
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.25 0.96 Not reported Not reported Not reported
Cough, Week 100 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 5
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.60 1.14 Not reported Not reported Not reported
Cough, Week 101 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 1.05 Not reported Not reported Not reported
Cough, Week 102 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 5
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 1.00 Not reported Not reported Not reported
Cough, Week 103 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 4
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.25 0.96 Not reported Not reported Not reported
Cough, Week 104 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 3
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.00 1.00 Not reported Not reported Not reported
Cough, Week 105 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 3
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.33 1.53 Not reported Not reported Not reported
Cough, Week 106 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab -0.50 0.71 Not reported Not reported Not reported
Cough, Week 107 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 3
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.00 1.00 Not reported Not reported Not reported
Cough, Week 108 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.00 1.41 Not reported Not reported Not reported
Cough, Week 109 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 2.12 Not reported Not reported Not reported
Cough, Week 110 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 2.12 Not reported Not reported Not reported
Cough, Week 111 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 2.12 Not reported Not reported Not reported
Cough, Week 112 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.00 1.41 Not reported Not reported Not reported
Cough, Week 113 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 2.12 Not reported Not reported Not reported
Cough, Week 114 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 2.12 Not reported Not reported Not reported
Cough, Week 115 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 2.12 Not reported Not reported Not reported
Cough, Week 116 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 2.12 Not reported Not reported Not reported
Cough, Week 117 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 2.12 Not reported Not reported Not reported
Cough, Week 118 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 2.12 Not reported Not reported Not reported
Cough, Week 119 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.50 2.12 Not reported Not reported Not reported
Cough, Week 120 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Cough, Week 121 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Cough, Week 122 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Cough, Week 123 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Cough, Week 124 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Cough, Week 125 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Cough, Week 126 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Cough, Week 127 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Cough, Week 128 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Cough, Week 129 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Cough, Week 130 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Cough, Week 131 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.00 Not reported Not reported Not reported Not reported
Dyspnoea, Week 1 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 44 Atezolizumab 47
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.42 0.81 Not reported Not reported Not reported Atezolizumab 0.12 0.76 Not reported Not reported Not reported
Dyspnoea, Week 2 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 42 Atezolizumab 48
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.33 0.73 Not reported Not reported Not reported Atezolizumab 0.29 0.87 Not reported Not reported Not reported
Dyspnoea, Week 3 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 44 Atezolizumab 49
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.25 0.75 Not reported Not reported Not reported Atezolizumab 0.25 0.97 Not reported Not reported Not reported
Dyspnoea, Week 4 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 41 Atezolizumab 49
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.43 0.87 Not reported Not reported Not reported Atezolizumab 0.28 0.89 Not reported Not reported Not reported
Dyspnoea, Week 5 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 39 Atezolizumab 47
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.55 0.81 Not reported Not reported Not reported Atezolizumab 0.21 1.00 Not reported Not reported Not reported
Dyspnoea, Week 6 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 33 Atezolizumab 48
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.68 Not reported Not reported Not reported Atezolizumab 0.21 0.95 Not reported Not reported Not reported
Dyspnoea, Week 7 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 30 Atezolizumab 44
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.63 0.74 Not reported Not reported Not reported Atezolizumab 0.32 1.08 Not reported Not reported Not reported
Dyspnoea, Week 8 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 29 Atezolizumab 44
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.64 Not reported Not reported Not reported Atezolizumab 0.25 1.00 Not reported Not reported Not reported
Dyspnoea, Week 9 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 31 Atezolizumab 47
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.46 0.86 Not reported Not reported Not reported Atezolizumab 0.34 1.01 Not reported Not reported Not reported
Dyspnoea, Week 10 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 30 Atezolizumab 40
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.43 0.80 Not reported Not reported Not reported Atezolizumab 0.49 1.12 Not reported Not reported Not reported
Dyspnoea, Week 11 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 29 Atezolizumab 34
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.36 0.77 Not reported Not reported Not reported Atezolizumab 0.24 0.97 Not reported Not reported Not reported
Dyspnoea, Week 12 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 32 Atezolizumab 40
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.39 0.82 Not reported Not reported Not reported Atezolizumab 0.35 1.04 Not reported Not reported Not reported
Dyspnoea, Week 13 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 28 Atezolizumab 38
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.43 0.83 Not reported Not reported Not reported Atezolizumab 0.23 0.94 Not reported Not reported Not reported
Dyspnoea, Week 14 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 28 Atezolizumab 35
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.26 0.88 Not reported Not reported Not reported Atezolizumab 0.26 1.14 Not reported Not reported Not reported
Dyspnoea, Week 15 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 30 Atezolizumab 40
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.36 1.07 Not reported Not reported Not reported Atezolizumab 0.39 1.22 Not reported Not reported Not reported
Dyspnoea, Week 16 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 25 Atezolizumab 32
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.18 0.82 Not reported Not reported Not reported Atezolizumab 0.26 1.13 Not reported Not reported Not reported
Dyspnoea, Week 17 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 27 Atezolizumab 34
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.48 0.87 Not reported Not reported Not reported Atezolizumab 0.16 1.17 Not reported Not reported Not reported
Dyspnoea, Week 18 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 23 Atezolizumab 37
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.39 0.65 Not reported Not reported Not reported Atezolizumab 0.21 1.05 Not reported Not reported Not reported
Dyspnoea, Week 19 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 22 Atezolizumab 32
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.29 0.86 Not reported Not reported Not reported Atezolizumab 0.33 1.12 Not reported Not reported Not reported
Dyspnoea, Week 20 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 22 Atezolizumab 35
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.60 0.87 Not reported Not reported Not reported Atezolizumab 0.23 1.00 Not reported Not reported Not reported
Dyspnoea, Week 21 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 18 Atezolizumab 36
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.27 0.69 Not reported Not reported Not reported Atezolizumab 0.40 0.93 Not reported Not reported Not reported
Dyspnoea, Week 22 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 20 Atezolizumab 35
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.55 0.92 Not reported Not reported Not reported Atezolizumab 0.22 0.99 Not reported Not reported Not reported
Dyspnoea, Week 23 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 16 Atezolizumab 33
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.34 0.69 Not reported Not reported Not reported Atezolizumab 0.38 0.98 Not reported Not reported Not reported
Dyspnoea, Week 24 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 16 Atezolizumab 33
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.36 1.02 Not reported Not reported Not reported Atezolizumab 0.42 1.06 Not reported Not reported Not reported
Dyspnoea, Week 25 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 29
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.22 0.46 Not reported Not reported Not reported Atezolizumab 0.50 1.14 Not reported Not reported Not reported
Dyspnoea, Week 26 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 13 Atezolizumab 32
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.32 0.82 Not reported Not reported Not reported Atezolizumab 0.28 0.95 Not reported Not reported Not reported
Dyspnoea, Week 27 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 32
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.35 1.07 Not reported Not reported Not reported Atezolizumab 0.37 1.04 Not reported Not reported Not reported
Dyspnoea, Week 28 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 30
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.35 0.92 Not reported Not reported Not reported Atezolizumab 0.45 0.83 Not reported Not reported Not reported
Dyspnoea, Week 29 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 12 Atezolizumab 28
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.20 0.89 Not reported Not reported Not reported Atezolizumab 0.38 0.85 Not reported Not reported Not reported
Dyspnoea, Week 30 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 12 Atezolizumab 30
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.18 0.96 Not reported Not reported Not reported Atezolizumab 0.54 1.01 Not reported Not reported Not reported
Dyspnoea, Week 31 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 29
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.18 0.84 Not reported Not reported Not reported Atezolizumab 0.41 0.86 Not reported Not reported Not reported
Dyspnoea, Week 32 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 23
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.22 1.00 Not reported Not reported Not reported Atezolizumab 0.58 1.04 Not reported Not reported Not reported
Dyspnoea, Week 33 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 13 Atezolizumab 26
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.20 0.78 Not reported Not reported Not reported Atezolizumab 0.36 0.96 Not reported Not reported Not reported
Dyspnoea, Week 34 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 10 Atezolizumab 26
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.16 0.79 Not reported Not reported Not reported Atezolizumab 0.28 1.00 Not reported Not reported Not reported
Dyspnoea, Week 35 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 27
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.11 0.58 Not reported Not reported Not reported Atezolizumab 0.27 1.02 Not reported Not reported Not reported
Dyspnoea, Week 36 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 9 Atezolizumab 25
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.11 0.86 Not reported Not reported Not reported Atezolizumab -0.02 1.04 Not reported Not reported Not reported
Dyspnoea, Week 37 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 8 Atezolizumab 23
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.28 0.63 Not reported Not reported Not reported Atezolizumab 0.42 1.13 Not reported Not reported Not reported
Dyspnoea, Week 38 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 11 Atezolizumab 21
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.40 0.76 Not reported Not reported Not reported Atezolizumab 0.50 1.25 Not reported Not reported Not reported
Dyspnoea, Week 39 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 9 Atezolizumab 22
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.27 0.81 Not reported Not reported Not reported Atezolizumab 0.25 0.86 Not reported Not reported Not reported
Dyspnoea, Week 40 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 7 Atezolizumab 23
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.57 0.76 Not reported Not reported Not reported Atezolizumab 0.44 1.13 Not reported Not reported Not reported
Dyspnoea, Week 41 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 7 Atezolizumab 20
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.31 0.58 Not reported Not reported Not reported Atezolizumab 0.53 1.17 Not reported Not reported Not reported
Dyspnoea, Week 42 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 6 Atezolizumab 20
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.30 0.55 Not reported Not reported Not reported Atezolizumab 0.52 1.07 Not reported Not reported Not reported
Dyspnoea, Week 43 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 5 Atezolizumab 20
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.40 0.57 Not reported Not reported Not reported Atezolizumab 0.41 1.18 Not reported Not reported Not reported
Dyspnoea, Week 44 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 7 Atezolizumab 19
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.49 0.60 Not reported Not reported Not reported Atezolizumab 0.31 1.14 Not reported Not reported Not reported
Dyspnoea, Week 45 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 21
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.65 0.38 Not reported Not reported Not reported Atezolizumab 0.53 1.04 Not reported Not reported Not reported
Dyspnoea, Week 46 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 5 Atezolizumab 19
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.56 0.71 Not reported Not reported Not reported Atezolizumab 0.37 0.97 Not reported Not reported Not reported
Dyspnoea, Week 47 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 18
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.30 0.68 Not reported Not reported Not reported Atezolizumab 0.39 0.92 Not reported Not reported Not reported
Dyspnoea, Week 48 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 15
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.60 0.72 Not reported Not reported Not reported Atezolizumab 0.39 0.93 Not reported Not reported Not reported
Dyspnoea, Week 49 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 17
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.40 1.20 Not reported Not reported Not reported Atezolizumab 0.47 0.76 Not reported Not reported Not reported
Dyspnoea, Week 50 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 5 Atezolizumab 15
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.24 0.59 Not reported Not reported Not reported Atezolizumab 0.53 0.96 Not reported Not reported Not reported
Dyspnoea, Week 51 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 16
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.05 1.02 Not reported Not reported Not reported Atezolizumab 0.59 1.02 Not reported Not reported Not reported
Dyspnoea, Week 52 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.10 1.01 Not reported Not reported Not reported Atezolizumab 0.72 1.20 Not reported Not reported Not reported
Dyspnoea, Week 53 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 5 Atezolizumab 12
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.76 1.28 Not reported Not reported Not reported Atezolizumab 0.40 1.01 Not reported Not reported Not reported
Dyspnoea, Week 54 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 14
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.10 1.16 Not reported Not reported Not reported Atezolizumab 0.63 1.02 Not reported Not reported Not reported
Dyspnoea, Week 55 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.00 0.53 Not reported Not reported Not reported Atezolizumab 0.72 1.13 Not reported Not reported Not reported
Dyspnoea, Week 56 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 4 Atezolizumab 14
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.40 0.86 Not reported Not reported Not reported Atezolizumab 0.61 1.07 Not reported Not reported Not reported
Dyspnoea, Week 57 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.53 0.61 Not reported Not reported Not reported Atezolizumab 0.45 1.02 Not reported Not reported Not reported
Dyspnoea, Week 58 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.80 0.53 Not reported Not reported Not reported Atezolizumab 0.60 1.20 Not reported Not reported Not reported
Dyspnoea, Week 59 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.60 0.72 Not reported Not reported Not reported Atezolizumab 0.18 1.08 Not reported Not reported Not reported
Dyspnoea, Week 60 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1.20 1.13 Not reported Not reported Not reported Atezolizumab 0.57 0.89 Not reported Not reported Not reported
Dyspnoea, Week 61 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 14
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.73 0.76 Not reported Not reported Not reported Atezolizumab 0.54 1.00 Not reported Not reported Not reported
Dyspnoea, Week 62 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 3 Atezolizumab 14
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.67 0.83 Not reported Not reported Not reported Atezolizumab 0.66 1.11 Not reported Not reported Not reported
Dyspnoea, Week 63 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 12
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.30 0.42 Not reported Not reported Not reported Atezolizumab 0.77 0.80 Not reported Not reported Not reported
Dyspnoea, Week 64 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 10
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.20 Not reported Not reported Not reported Not reported Atezolizumab 0.66 1.07 Not reported Not reported Not reported
Dyspnoea, Week 65 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 13
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.60 Not reported Not reported Not reported Not reported Atezolizumab 0.94 1.28 Not reported Not reported Not reported
Dyspnoea, Week 66 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 11
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.40 Not reported Not reported Not reported Not reported Atezolizumab 0.67 1.31 Not reported Not reported Not reported
Dyspnoea, Week 67 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 11
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.14 Not reported Not reported Not reported Atezolizumab 0.33 0.87 Not reported Not reported Not reported
Dyspnoea, Week 68 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.20 0.28 Not reported Not reported Not reported Atezolizumab 0.82 1.56 Not reported Not reported Not reported
Dyspnoea, Week 69 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 10
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.30 0.42 Not reported Not reported Not reported Atezolizumab 0.74 1.11 Not reported Not reported Not reported
Dyspnoea, Week 70 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 11
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.30 0.42 Not reported Not reported Not reported Atezolizumab 0.75 1.16 Not reported Not reported Not reported
Dyspnoea, Week 71 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 10
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.10 0.14 Not reported Not reported Not reported Atezolizumab 0.84 1.19 Not reported Not reported Not reported
Dyspnoea, Week 72 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 12
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.80 1.09 Not reported Not reported Not reported
Dyspnoea, Week 73 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 11
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.00 Not reported Not reported Not reported Not reported Atezolizumab 0.67 1.11 Not reported Not reported Not reported
Dyspnoea, Week 74 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.20 0.28 Not reported Not reported Not reported Atezolizumab 0.89 1.35 Not reported Not reported Not reported
Dyspnoea, Week 75 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.30 0.42 Not reported Not reported Not reported Atezolizumab 0.71 1.31 Not reported Not reported Not reported
Dyspnoea, Week 76 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 8
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.30 0.42 Not reported Not reported Not reported Atezolizumab 0.53 1.05 Not reported Not reported Not reported
Dyspnoea, Week 77 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 8
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.40 0.57 Not reported Not reported Not reported Atezolizumab 0.65 1.55 Not reported Not reported Not reported
Dyspnoea, Week 78 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.30 0.14 Not reported Not reported Not reported Atezolizumab 0.40 1.11 Not reported Not reported Not reported
Dyspnoea, Week 79 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 8
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.10 0.14 Not reported Not reported Not reported Atezolizumab 0.55 1.25 Not reported Not reported Not reported
Dyspnoea, Week 80 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 9
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.50 0.71 Not reported Not reported Not reported Atezolizumab 0.69 1.43 Not reported Not reported Not reported
Dyspnoea, Week 81 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 2 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.40 0.57 Not reported Not reported Not reported Atezolizumab 0.53 1.53 Not reported Not reported Not reported
Dyspnoea, Week 82 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.60 Not reported Not reported Not reported Not reported Atezolizumab 0.53 1.09 Not reported Not reported Not reported
Dyspnoea, Week 83 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.60 Not reported Not reported Not reported Not reported Atezolizumab 0.87 1.28 Not reported Not reported Not reported
Dyspnoea, Week 84 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.80 Not reported Not reported Not reported Not reported Atezolizumab 0.89 1.13 Not reported Not reported Not reported
Dyspnoea, Week 85 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 8
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.60 Not reported Not reported Not reported Not reported Atezolizumab 0.83 1.27 Not reported Not reported Not reported
Dyspnoea, Week 86 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.40 Not reported Not reported Not reported Not reported Atezolizumab 0.66 1.33 Not reported Not reported Not reported
Dyspnoea, Week 87 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 1 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0.40 Not reported Not reported Not reported Not reported Atezolizumab 0.66 1.23 Not reported Not reported Not reported
Dyspnoea, Week 88 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.20 1.43 Not reported Not reported Not reported
Dyspnoea, Week 89 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 5
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.56 1.05 Not reported Not reported Not reported
Dyspnoea, Week 90 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.74 1.38 Not reported Not reported Not reported
Dyspnoea, Week 91 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.51 1.00 Not reported Not reported Not reported
Dyspnoea, Week 92 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.87 1.26 Not reported Not reported Not reported
Dyspnoea, Week 93 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.20 1.39 Not reported Not reported Not reported
Dyspnoea, Week 94 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 5
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.48 0.99 Not reported Not reported Not reported
Dyspnoea, Week 95 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.87 1.32 Not reported Not reported Not reported
Dyspnoea, Week 96 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.13 1.24 Not reported Not reported Not reported
Dyspnoea, Week 97 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 7
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.26 1.35 Not reported Not reported Not reported
Dyspnoea, Week 98 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.80 1.19 Not reported Not reported Not reported
Dyspnoea, Week 99 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 4
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.70 1.58 Not reported Not reported Not reported
Dyspnoea, Week 100 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 5
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.88 1.38 Not reported Not reported Not reported
Dyspnoea, Week 101 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 6
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.13 1.54 Not reported Not reported Not reported
Dyspnoea, Week 102 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 5
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.96 1.58 Not reported Not reported Not reported
Dyspnoea, Week 103 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 4
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.55 1.68 Not reported Not reported Not reported
Dyspnoea, Week 104 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 3
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.07 1.33 Not reported Not reported Not reported
Dyspnoea, Week 105 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 3
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.07 1.33 Not reported Not reported Not reported
Dyspnoea, Week 106 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 0.40 0.28 Not reported Not reported Not reported
Dyspnoea, Week 107 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 3
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.13 1.63 Not reported Not reported Not reported
Dyspnoea, Week 108 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.50 1.56 Not reported Not reported Not reported
Dyspnoea, Week 109 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.30 1.27 Not reported Not reported Not reported
Dyspnoea, Week 110 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.50 1.56 Not reported Not reported Not reported
Dyspnoea, Week 111 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.60 1.41 Not reported Not reported Not reported
Dyspnoea, Week 112 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.50 1.56 Not reported Not reported Not reported
Dyspnoea, Week 113 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.50 1.56 Not reported Not reported Not reported
Dyspnoea, Week 114 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.60 1.70 Not reported Not reported Not reported
Dyspnoea, Week 115 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.40 1.41 Not reported Not reported Not reported
Dyspnoea, Week 116 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.30 1.27 Not reported Not reported Not reported
Dyspnoea, Week 117 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.50 1.56 Not reported Not reported Not reported
Dyspnoea, Week 118 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.30 1.27 Not reported Not reported Not reported
Dyspnoea, Week 119 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 2
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 1.50 1.56 Not reported Not reported Not reported
Dyspnoea, Week 120 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.20 Not reported Not reported Not reported Not reported
Dyspnoea, Week 121 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.40 Not reported Not reported Not reported Not reported
Dyspnoea, Week 122 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.20 Not reported Not reported Not reported Not reported
Dyspnoea, Week 123 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.20 Not reported Not reported Not reported Not reported
Dyspnoea, Week 124 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.20 Not reported Not reported Not reported Not reported
Dyspnoea, Week 125 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.20 Not reported Not reported Not reported Not reported
Dyspnoea, Week 126 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.20 Not reported Not reported Not reported Not reported
Dyspnoea, Week 127 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.20 Not reported Not reported Not reported Not reported
Dyspnoea, Week 128 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.20 Not reported Not reported Not reported Not reported
Dyspnoea, Week 129 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.20 Not reported Not reported Not reported Not reported
Dyspnoea, Week 130 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.20 Not reported Not reported Not reported Not reported
Dyspnoea, Week 131 Analysis denominator · Participants
Group Source count Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) 0 Atezolizumab 1
Values in Score on a scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Atezolizumab 2.20 Not reported Not reported Not reported Not reported
Complete source fields classes categories measurements
group Id OG000
spread 1.23
value 0.57
group Id OG001
spread 0.84
value 0.31 denoms counts
group Id OG000
value 44
group Id OG001
value 47
units Participants
title Chest Pain, Week 1 categories measurements
group Id OG000
spread 1.13
value 0.42
group Id OG001
spread 0.85
value 0.33 denoms counts
group Id OG000
value 42
group Id OG001
value 48
units Participants
title Chest Pain, Week 2 categories measurements
group Id OG000
spread 1.26
value 0.25
group Id OG001
spread 0.97
value 0.43 denoms counts
group Id OG000
value 44
group Id OG001
value 49
units Participants
title Chest Pain, Week 3 categories measurements
group Id OG000
spread 1.21
value 0.15
group Id OG001
spread 1.08
value 0.43 denoms counts
group Id OG000
value 41
group Id OG001
value 49
units Participants
title Chest Pain, Week 4 categories measurements
group Id OG000
spread 1.19
value 0.27
group Id OG001
spread 1.00
value 0.28 denoms counts
group Id OG000
value 39
group Id OG001
value 47
units Participants
title Chest Pain, Week 5 categories measurements
group Id OG000
spread 1.26
value 0.30
group Id OG001
spread 0.85
value 0.25 denoms counts
group Id OG000
value 33
group Id OG001
value 48
units Participants
title Chest Pain, Week 6 categories measurements
group Id OG000
spread 1.04
value 0.23
group Id OG001
spread 0.97
value 0.30 denoms counts
group Id OG000
value 30
group Id OG001
value 44
units Participants
title Chest Pain, Week 7 categories measurements
group Id OG000
spread 1.12
value 0.17
group Id OG001
spread 0.82
value 0.20 denoms counts
group Id OG000
value 29
group Id OG001
value 44
units Participants
title Chest Pain, Week 8 categories measurements
group Id OG000
spread 1.00
value 0.27
group Id OG001
spread 1.07
value 0.33 denoms counts
group Id OG000
value 31
group Id OG001
value 47
units Participants
title Chest Pain, Week 9 categories measurements
group Id OG000
spread 1.13
value 0.30
group Id OG001
spread 1.12
value 0.25 denoms counts
group Id OG000
value 30
group Id OG001
value 40
units Participants
title Chest Pain, Week 10 categories measurements
group Id OG000
spread 1.32
value 0.26
group Id OG001
spread 0.96
value 0.21 denoms counts
group Id OG000
value 29
group Id OG001
value 34
units Participants
title Chest Pain, Week 11 categories measurements
group Id OG000
spread 1.33
value 0.22
group Id OG001
spread 0.97
value 0.33 denoms counts
group Id OG000
value 32
group Id OG001
value 40
units Participants
title Chest Pain, Week 12 Show more (12 of 393) denoms counts
group Id OG000
value 52
group Id OG001
value 61
units Participants
description Change from baseline in each of the patient-reported lung cancer symptoms with use of the SILC scale. The SILC scale is a nine-item content valid self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a total symptom severity score. Each SILC symptom scale (dyspnea, cough, chest pain) score was calculated as the average of the component items (range 0 to 4). An increase in score suggested worsening in symptomatology. A symptom score change of 0.3 points for the dyspnea and cough scores was considered to be clinically significant; whereas a symptom score change of 0.5 points for the chest pain score was considered to be clinically significant.
dispersion Type Standard Deviation groups
description Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).
Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).
id OG000
title Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)
description Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
id OG001
title Atezolizumab
param Type MEAN
population Description Analysis was performed for the TC3 or IC3-WT Populations.
reporting Status POSTED
time Frame Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)
title Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations
type SECONDARY
unit Of Measure Score on a scale Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle